Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...
Hosted on MSN
Combination therapy could expand treatment options for AML patients and extend survival
Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work well in multiple myeloma. Subscribe to our ...
We created a publicly available software library, shinyCox, that can generate user-friendly interactive applications to visualize survival outcome predictions of fitted Cox models. To illustrate the ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...
For Shirley*, a retired professor and author living in Arizona, life has always been about travel, new adventures and musical performance. Alongside her husband, Jim, and their beloved dog, Parker, ...
Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work well in multiple myeloma. A new study by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results